https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46788 Wed 30 Nov 2022 13:21:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24235 Wed 11 Apr 2018 14:55:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53619 Wed 07 Feb 2024 14:40:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50157 Wed 05 Jul 2023 15:21:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51126 Tue 22 Aug 2023 15:51:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51127 Tue 22 Aug 2023 15:51:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9874 Sat 24 Mar 2018 08:12:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26171 Sat 24 Mar 2018 07:30:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39177 n = 133). Participants received 16 weeks adjunctive treatment of either placebo or N-acetylcysteine-alone or a combination of mitochondrial-enhancing nutraceuticals including N-acetylcysteine (combination treatment). Participants were followed up 4 weeks post-treatment discontinuation (Week 20). Diet was assessed by the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies, Version 2, converted into an Australian Recommended Food Score to measure diet quality, and energy-adjusted dietary inflammatory index score to measure inflammatory potential of diet. Body mass index was also measured. Generalised estimating equation models were used to assess whether diet quality, energy-adjusted dietary inflammatory index score and/or body mass index were predictors of response to significant outcomes of the primary trial: depression symptoms, clinician-rated improvement and functioning measures. Results: In participants taking combination treatment compared to placebo, change in depression scores was not predicted by Australian Recommended Food Score, dietary inflammatory index or body mass index scores. However, participants with better diet quality (Australian Recommended Food Score) reported reduced general depression and bipolar depression symptoms (p = 0.01 and p = 0.03, respectively) and greater clinician-rated improvement (p = 0.02) irrespective of treatment and time. Participants who had a more anti-inflammatory dietary inflammatory index had less impairment in functioning (p = 0.01). Combination treatment may attenuate the adverse effects of pro-inflammatory diet (p = 0.03) on functioning. Participants with lower body mass index who received combination treatment (p = 0.02) or N-acetylcysteine (p = 0.02) showed greater clinician-rated improvement. Conclusion: These data support a possible association between diet (quality and inflammatory potential), body mass index and response to treatment for bipolar depression in the context of a nutraceutical trial. The results should be interpreted cautiously because of limitations, including numerous null findings, modest sample size and being secondary analyses.]]> Mon 23 May 2022 14:53:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51396 Mon 04 Sep 2023 14:43:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45466 n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.]]> Fri 28 Oct 2022 14:45:19 AEDT ]]>